RS63338B1 - Proces pripreme dva derivata 4-{[(2s)-2-{4-[5-hloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida - Google Patents

Proces pripreme dva derivata 4-{[(2s)-2-{4-[5-hloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida

Info

Publication number
RS63338B1
RS63338B1 RS20220611A RSP20220611A RS63338B1 RS 63338 B1 RS63338 B1 RS 63338B1 RS 20220611 A RS20220611 A RS 20220611A RS P20220611 A RSP20220611 A RS P20220611A RS 63338 B1 RS63338 B1 RS 63338B1
Authority
RS
Serbia
Prior art keywords
oxopyridin
butanoyl
triazol
chloro
methoxy
Prior art date
Application number
RS20220611A
Other languages
English (en)
Inventor
Julian Egger
Daniel Götz
Michal Sowa
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of RS63338B1 publication Critical patent/RS63338B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RS20220611A 2018-03-15 2019-03-08 Proces pripreme dva derivata 4-{[(2s)-2-{4-[5-hloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida RS63338B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18161983 2018-03-15
EP19708556.6A EP3765452B1 (en) 2018-03-15 2019-03-08 Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives
PCT/EP2019/055815 WO2019175043A1 (en) 2018-03-15 2019-03-08 Preparative process of two 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide derivatives

Publications (1)

Publication Number Publication Date
RS63338B1 true RS63338B1 (sr) 2022-07-29

Family

ID=61683650

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20220611A RS63338B1 (sr) 2018-03-15 2019-03-08 Proces pripreme dva derivata 4-{[(2s)-2-{4-[5-hloro-2-(1h-1,2,3-triazol-1-il)fenil]-5-metoksi-2-oksopiridin-1(2h)-il}butanoil]amino}-2-fluorobenzamida

Country Status (28)

Country Link
US (1) US11542245B2 (sr)
EP (2) EP3765452B1 (sr)
JP (1) JP7287978B2 (sr)
KR (1) KR20200131241A (sr)
CN (1) CN111770917B (sr)
AR (1) AR117400A1 (sr)
AU (1) AU2019236369B2 (sr)
BR (1) BR112020018562A2 (sr)
CA (1) CA3093733A1 (sr)
CL (1) CL2020002371A1 (sr)
DK (1) DK3765452T3 (sr)
ES (1) ES2920449T3 (sr)
HR (1) HRP20220565T1 (sr)
HU (1) HUE058796T2 (sr)
IL (2) IL277240B2 (sr)
JO (1) JOP20200232B1 (sr)
LT (1) LT3765452T (sr)
MX (1) MX2020009580A (sr)
PE (1) PE20211395A1 (sr)
PL (1) PL3765452T3 (sr)
PT (1) PT3765452T (sr)
RS (1) RS63338B1 (sr)
SG (1) SG11202006710RA (sr)
SI (1) SI3765452T1 (sr)
TW (1) TWI823911B (sr)
UA (1) UA126940C2 (sr)
UY (1) UY38147A (sr)
WO (1) WO2019175043A1 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140558A (ko) * 2020-02-11 2022-10-18 케미노바 에이/에스 (r)-2-아미노부탄산으로부터 s-베플루부타미드를 합성하는 방법
JP2024508970A (ja) 2021-03-09 2024-02-28 バイエル・アクチエンゲゼルシヤフト （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－ジベンゼナヘプタファン－７４－カルボキサミドを含んでいる医薬剤形
WO2022189280A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide
JP2024508971A (ja) 2021-03-09 2024-02-28 バイエル・アクチエンゲゼルシヤフト （４ｓ）－２４－クロロ－４－エチル－７３－フルオロ－３５－メトキシ－３２，５－ジオキソ－１４－（トリフルオロメチル）－３２ｈ－６－アザ－３（４，１）－ピリジナ－１（１）－［１，２，３］トリアゾラ－２（１，２），７（１）－５ ジベンゼナヘプタファン－７４－カルボキサミドの結晶形態
WO2023174399A1 (zh) * 2022-03-18 2023-09-21 苏州晶云药物科技股份有限公司 取代的氧代吡啶类衍生物的晶型及其制备方法
CN116082303A (zh) * 2022-12-21 2023-05-09 成都施贝康生物医药科技有限公司 新型氧代吡啶类化合物及其中间体和应用
CN116535392B (zh) * 2023-06-26 2023-09-05 成都施贝康生物医药科技有限公司 一种氧代吡啶类化合物的制备方法及中间体和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0107456A (pt) 2000-01-07 2002-10-08 Transform Pharmaceuticals Inc Formação de amostras, métodos de preparar uma formação de múltiplas formas sólidas de um composto de interesse, de triar uma pluralidade de formas sólidas de um composto de interesse e condições e/ou componentes para compatibilidade com uma ou mais formas sólidas selecionadas de um composto de interesse, de identificar formas sólidas ótimas de um composto de interesse e de determinar conjuntos de condições e/ou componentes para produzir formas sólidas de um composto de interesse, um conjunto de parâmetros de processamento e/ou componentes e as condições e/ou componentes que produzem um composto de interesse ou um seu derivado diastereomérico e sistema para identificar formas sólidas ótimas de um composto de interesse
TWI633089B (zh) 2013-03-28 2018-08-21 拜耳製藥股份有限公司 經取代的酮基吡啶衍生物
JO3703B1 (ar) 2015-07-09 2021-01-31 Bayer Pharma AG مشتقات أوكسوبيريدين مستبدلة
CN107793396B (zh) 2016-08-31 2021-02-26 江苏恒瑞医药股份有限公司 环氧基取代的氧代吡啶类衍生物、其制备方法及其在医药上的应用
EP3898611A1 (en) * 2018-12-17 2021-10-27 Bayer Aktiengesellschaft Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications
KR20210106504A (ko) * 2018-12-21 2021-08-30 바이엘 악티엔게젤샤프트 치환된 옥소피리딘 유도체
US20220144848A1 (en) * 2018-12-21 2022-05-12 Bayer Aktiengesellschaft Substituted oxopyridine derivatives

Also Published As

Publication number Publication date
AR117400A1 (es) 2021-08-04
HUE058796T2 (hu) 2022-09-28
IL277240A (en) 2020-10-29
SI3765452T1 (sl) 2022-06-30
CA3093733A1 (en) 2019-09-19
IL277240B2 (en) 2024-01-01
BR112020018562A2 (pt) 2020-12-29
UA126940C2 (uk) 2023-02-22
PL3765452T3 (pl) 2022-08-01
CL2020002371A1 (es) 2021-01-29
SG11202006710RA (en) 2020-08-28
EP3765452A1 (en) 2021-01-20
TW202002969A (zh) 2020-01-16
US11542245B2 (en) 2023-01-03
JOP20200232A1 (ar) 2020-09-14
KR20200131241A (ko) 2020-11-23
JP7287978B2 (ja) 2023-06-06
PE20211395A1 (es) 2021-07-27
JOP20200232B1 (ar) 2023-09-17
AU2019236369A1 (en) 2020-07-30
EP3765452B1 (en) 2022-04-13
LT3765452T (lt) 2022-05-25
RU2020133706A (ru) 2022-04-18
JP2021517573A (ja) 2021-07-26
US20210017152A1 (en) 2021-01-21
ES2920449T3 (es) 2022-08-04
IL277240B1 (en) 2023-09-01
WO2019175043A1 (en) 2019-09-19
PT3765452T (pt) 2022-06-23
IL300463A (en) 2023-04-01
DK3765452T3 (da) 2022-06-27
HRP20220565T1 (hr) 2022-06-10
AU2019236369B2 (en) 2024-04-18
UY38147A (es) 2019-10-01
EP3889147A1 (en) 2021-10-06
MX2020009580A (es) 2020-10-05
CN111770917B (zh) 2023-09-26
CN111770917A (zh) 2020-10-13
TWI823911B (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
IL277240A (en) Process for the preparation of two derivatives of 4-{[(2S)-2-{4-[5-chloro-2-(1H-3,2,1-triazol-1-yl)phenyl]-5-methoxy-2-oxopyridine -1-(2H)-yl}butenoyl]amino}-2-fluorobenzamide
EP4103563A4 (en) HETEROCYCLIC GLP-1 AGONISTS
NZ745957A (en) Heterocyclic amides useful as protein modulators
EP4143183A4 (en) HETEROCYCLIC GLP-1 AGONISTS
EP4192831A4 (en) HETEROCYCLIC GLP-1 AGONISTS
SG11202102057SA (en) Process for the preparation of methyl 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylate
EP3411036A4 (en) 3,5-DISUBSTITUTED PYRAZOLE AS CHECKPOINT KINASE 1 (CHK1) INHIBITORS, AND THEIR PREPARATION AND USE
DK3724191T3 (da) 5-(2-(2,5-difluorphenyl)pyrrolidin-1-yl)-3-(1h-pyrazol-1-yl)pyrazol[1,5-a]pyrimidinderivater og lignende forbindelser som trk-kinasehæmmere til cancerbehandling
HUE059506T2 (hu) Az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-maleát kristályos formájának elõállítási eljárása és az 1-((2R,4R)-2-(1H-benzo[d]imidazol-2-il)-1-metilpiperidin-4-il)-3-(4--cianofenil)karbamid-imidazol komplex (1:1) kristályos formája
EP4028393A4 (en) 3,5-DISUBSTITUTED PYRAZOLE COMPOUNDS AS KINAS INHIBITORS AND THEIR USES
EP3394039A4 (en) SALT FORMS AND POLYMORPHS OF (R) -1- (4- (6- (2- (4- (3,3-DIFLUOROCYCLOBUTOXY) -6-METHYLPYRIDIN-2-YL) ACETAMIDO) PYRIDAZIN-3-YL) -2 -FLUOROBUTYL) -N-METHYL-1H-1,2,3-triazole-4-carboxamide
MX2019011513A (es) Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il )piperazina.
EP3233824A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
MX2019015612A (es) Composicion farmaceutica y metodo para preparar el mismo.
PH12017500123A1 (en) Crystal of azole benzene derivative
PH12017500124A1 (en) Azole benzene derivative and crystalline form thereof
TWI849432B (zh) 製造5-(4-((2s,5s)-5-(4-氯芐基)-2-甲基嗎啉基)哌啶-1-基)-1h-1,2,4-三唑-3-胺的方法
RU2022129311A (ru) Способ получения двух 4-{ [(2s)-2-{ 4-[5-хлор-2-(1h-1,2,3-триазол-1-ил)фенил]-5-метокси-2-оксопиридин-1(2h)-ил} бутаноил]амино} -2-фторбензамидных производных
ZA202204542B (en) Process for the production of 5-(4-((2 s,5 s)-5-(4-chlorobenzyl)-2-methylmorpholino)piperidin-1-yl)-1 h-1,2,4-triazol-3-amine
IL307590A (en) 2-((4-((S)-2-(4-CHLORO-2-FLUOROPHENYL)-2-METHYLBENZO[D][1,3]DIOXOL-4-YL)PIPERIDIN-1-YL)METHYL)-1 -(((S)-OXETAN-2-YL)MTHYL)-1H-IMIDAZOLE DERIVATIVES AS ACTIVATORS OF THE GLP1 RECEPTOR FOR THE TREATMENT OF OBESITY
EP4017853A4 (en) HETEROCYCLIC PYRAZOL DERIVATIVES AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
MX2018008342A (es) Composicion farmaceutica que comprende un derivado azoico de pirazolona biciclo-sustituido o una sal del mismo y metodo de preparacion de los mismos.